AGMB
HEALTHCAREAgomAb Therapeutics NV American Depositary Shares
AI Insight
What's Moving AGMB Today?
No stock-specific AI insight has been generated for AGMB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.75$17.82
$12.98
Fundamentals
Market Cap$680M
P/E Ratio—
EPS$-1.46
Dividend Yield—
Dividend / Share—
ROE-39.2%
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding49.2M
AGMB News
11 articles- Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s DiseaseTaiwan News·Jun 24, 2026
- Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's DiseaseYahoo Finance·Jun 23, 2026
- Agomab Announces Results of Annual General MeetingGlobeNewswire Inc.·May 27, 2026
- Agomab to Participate in Upcoming ConferencesYahoo Finance·May 14, 2026
- Agomab Reports Full Year 2025 Financial Results and Confirms 2026 OutlookGlobeNewswire Inc.·Apr 23, 2026
- AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447Yahoo Finance·Apr 12, 2026
- Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewswire Inc.·Mar 26, 2026
- European Equities Traded in the US as American Depositary Receipts Higher WednesdayYahoo Finance·Feb 18, 2026
- Agomab Announces Closing of Initial Public OfferingYahoo Finance·Feb 9, 2026
- Agomab indicated to open at $15.50, IPO priced at $16Yahoo Finance·Feb 7, 2026
- Agomab Announces Pricing of Initial Public OfferingYahoo Finance·Feb 6, 2026
All 11 articles loaded
Price Data
Open$17.60
Previous Close$17.82
Day High$17.75
Day Low$12.52
52 Week High$17.82
52 Week Low$8.75
52-Week Range
$8.75$17.82
$12.98
Fundamentals
Market Cap$680M
P/E Ratio—
EPS$-1.46
Dividend Yield—
Dividend / Share—
ROE-39.2%
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding49.2M
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company is headquartered in Antwerp, Belgium.
Listed February 6, 2026
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—